期刊文献+

奥氮平与喹硫平对小儿精神障碍患者不良反应及睡眠质量的影响 被引量:1

Effects of Olanzapine and Quetiapine on Adverse Reactions and Sleep Quality in Children with Mental Disorders
下载PDF
导出
摘要 目的:探究奥氮平与喹硫平对小儿精神障碍患者不良反应及睡眠质量的影响。方法:选取2016年1月至2017年9月北京大学第六医院收治的儿童青少年精神障碍患者78例作为研究对象,采用随机数字表法分为奥氮平组和喹硫平组,分别实施相应的药物治疗,试验周期为4周,比较2组患者治疗前后匹兹堡睡眠质量指数(PSQI)量表评分及治疗后不良反应的发生率。结果:奥氮平组患者治疗后不良反应的发生率显著高于喹硫平组,同时患者的不良反应中心动过缓、体质量增加、嗜睡、低血压的发生率均高于喹硫平组;喹硫平组患者心动过速的发生率显著高于奥氮平组,差异无统计学意义(P> 0. 05); 2组患者治疗前基线匹兹堡睡眠质量指数(PSQI)量表评分比较,差异无统计学意义(P> 0. 05),具有可比性;2组患者治疗前的PSQI基线评分均显著高于治疗后PSQI评分,差异有统计学意义(P <0. 05); 2组患者治疗后组间PSQI评分比较,差异无统计学意义(P> 0. 05)。结论:奥氮平与喹硫平对小儿精神障碍患者不良反应比较差异无统计学意义,同时2种药物在改善儿童青少年睡眠质量方面疗效佳且效能大致相同。 Objective: To investigate the effects of olanzapine and quetiapine on adverse reactions and sleep quality in children with mental disorders. Methods: A total of 78 children and adolescents with mental disorders in our hospital were enrolled from January 2016 to September 2017.They were randomly divided into olanzapine group and quetiapine group by random number table.Olanzapine group was given oral olanzapine tablets,while quetiapine group was given oral quetiapine tablets.The test period was 4 weeks,and the Pittsburgh Sleep Quality Index(PSQI)scale score and the incidence of adverse reactions after treatment were compared before and after treatment. Results: The incidence of adverse reactions after treatment in olanzapine group was significantly higher than those in quetiapine group.At the same time,the incidence of adverse reactions,weight gain,lethargy and hypotension were higher in olanzapine group than in quetiapine group.The incidence of tachycardia in quetiapine group was significantly higher than that of olanzapine group,and there was no significant difference between the two groups( P >0.05).And there was no significant difference in the baseline Pittsburgh Sleep Quality Index(PSQI)scale between the two groups( P >0.05).The scores of PSQI before treatment were significantly higher than after treatment( P <0.05).There was no significant difference in PSQI score between the two groups after treatment( P >0.05). Conclusion: There is no significant difference in the adverse reactions between olanzapine and quetiapine in children with mental disorders.At the same time,the two drugs are effective and have almost the same efficacy in improving the quality of sleep in children and adolescents.
作者 张磊 Zhang Lei(Children′s Ward,Sixth Hospital of Peking University,Beijing 100191,China)
出处 《世界睡眠医学杂志》 2019年第1期70-72,共3页 World Journal of Sleep Medicine
关键词 奥氮平 喹硫平 小儿精神障碍 不良反应 睡眠质量 Olanzapine Quetiapine Pediatric mental disorders Adverse reactions Sleep quality
  • 相关文献

参考文献4

二级参考文献48

  • 1周天红,孙凌.奥氮平在儿童精神障碍中的应用[J].临床精神医学杂志,2004,14(5):309-310. 被引量:10
  • 2王佶,王艺,高鸿云.儿童孤独症的诊治进展[J].国际儿科学杂志,2006,33(1):41-44. 被引量:27
  • 3张微,刘翔平,顾群,廖冉,冉俐雯.六城市ADHD流行病学调查[J].中国临床心理学杂志,2007,15(1):23-25. 被引量:65
  • 4徐惠琴,金嵘,郑荣远,张磊,邵蓓,何金彩,王旭华.Tourette综合征的发病危险因素分析[J].中国实用儿科杂志,2007,22(3):196-198. 被引量:3
  • 5LOCKLEA JC, WAHLGV1ST P, GUSTAFSSSON U,et al. Im- pact of extend-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysis [J]. J Comp EffRes, 2014,3(4) :335 -344.
  • 6DATTO C, BERGGREN L, PATEL JB,et al. Self-reported seda- tion profile of immediate-release quetiapine fumaratc compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects[ J ]. Clin Ther, 2009, 31 (3) :492 - 502.
  • 7NORD M, NYBERG S, BROGREN J,et al. Comparison of D2 dopamine receptor occupancy after oral administration of quetiap- ine fumarate immediate-release and extended-release formulations in healthy subjects[ J]. lnt J Neuropsychopharmacol, 2011, 14 (10) :1357 - 1366.
  • 8JENSEN NH, RODRIGUIZ RM, CARON MG. N-Desalylquetia- pine, a potent norepinephrine reuptake inhibitor and partial 5- HT1 A Agonist, as a putative mediator of quetiapine's antidepres- sant activity [ J ]. Neuropsychopharmacology, 2008,33 ( 10 ) : 2303 - 2312.
  • 9BUI K, EARLEY W, NYBERG S. Pharmaeokinetic profile ofthe extended-release formulation of quetiapine fumarate ( quetiap- ine XR) : clinical implications[ J], Curr Med Res Opin, 2013, 29(7) :813 -825.
  • 10COLDHAM EL, ADDINGTON J, ADDINGTON D. Medication adherence of individuals with a first episode of psychosis[ J]. Ac- ta Psychiatr Scand, 2002,106 (4) :286 - 290.

共引文献58

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部